# Case Study: Cross-Border Regulatory Sync (Rituximab)
**Date:** 2026-01-12  
**Tools:** OncoAudit LLM Parser + AO Permaweb Storage  

## 1. Objective
To monitor the synchronization gap (Drug Lag) between global regulatory bodies (US FDA, Japan MHLW, Taiwan TFDA) regarding the oncology drug **Rituximab**.

## 2. Raw Data Sources
- **US FDA:** [FDA Label Update PDF (Jan 2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103705s5367s5388lbl.pdf)
- **Japan MHLW:** [Meeting Minutes Jan 12, 2026](https://www.mhlw.go.jp/content/11121000/001629103.pdf)
- **Taiwan TFDA:** [Standard Drug Database Search](https://www.fda.gov.tw/TC/searchin.aspx)

## 3. Findings (The Audit Trail)
OncoAudit's parser identified a significant clinical protocol update:
- **US FDA (Jan 04):** Approved an expanded **8-week treatment cycle** for Rituximab.
- **Japan MHLW (Jan 12):** Japanese experts are currently reviewing the "Partial Change" to align with this international standard (Refer to Issue #5 in the PDF).
- **Taiwan TFDA (Current):** Still utilizing the legacy 4-week protocol, identifying a clear **Drug Lag** in local patient access to updated treatments.

## 4. AO Implementation Proof
This regulatory event has been structured and sealed on the AO Permaweb.
- **Process ID:** `TBD` (Waiting for deployment)
- **Data Schema:** ```json
{
  "drug": "Rituximab",
  "event": "Dosage Cycle Alignment",
  "gap_detected": "8-day lag (US vs JP)"
}
